Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 368 shares, a growth of 44.9% from the December 15th total of 254 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 3,296 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 3,296 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.Ascentage Pharma Group International Stock PerformanceShares of AAPG opened at $27.05 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 1-year low of $16.50 and a 1-year high of $48.45. The company has a 50-day moving average of $29.68 and a 200 day moving average of $35.81. Institutional Trading of Ascentage Pharma Group InternationalInstitutional investors and hedge funds have recently made changes to their positions in the company. Chevy Chase Trust Holdings LLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $227,000. Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $610,000. UBS Group AG increased its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the second quarter worth approximately $391,000. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the third quarter worth $383,000. Analyst Upgrades and DowngradesA number of research analysts recently commented on the stock. Oppenheimer started coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an "outperform" rating and a $45.00 price target for the company. Piper Sandler began coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an "overweight" rating and a $48.00 price objective for the company. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a report on Tuesday. They issued a "buy" rating and a $48.00 target price for the company. BTIG Research began coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Lucid Cap Mkts upgraded Ascentage Pharma Group International to a "strong-buy" rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $48.40.View Our Latest Report on Ascentage Pharma Group InternationalAbout Ascentage Pharma Group International (Get Free Report)Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors. Founded in 2008 by biotechnology entrepreneur Dr.Featured StoriesFive stocks we like better than Ascentage Pharma Group InternationalElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietlyExecutive Order 14330: Trump’s Biggest Yet“Fed Proof” Your Bank Account with THESE 4 Simple StepsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ascentage Pharma Group International Right Now?Before you consider Ascentage Pharma Group International, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here